Novartis AG (NVS) annual results, year to 31 December 2024: revenue USD 50,317 million, from the 20-F
Novartis AG files a 20-F with the SEC once a year, in US dollars. In the year to 31 December 2024 it reported revenue from the sale of goods of USD 50,317 million, up 10.7% on the year before. Its profit attributable to shareholders was USD 11,941 million, down 19.6%, and diluted earnings per share USD 5.87.
The year to 31 December 2024, against the year before
| Year to | Dec 2023 | Dec 2024 |
|---|---|---|
| Revenue from the sale of goods | 45,440 | 50,317 |
| Cost of sales | 12,472 | 12,827 |
| Gross profit | 34,188 | 38,895 |
| Research and development | 11,371 | 10,022 |
| Selling, general and administrative | 12,517 | 12,566 |
| Operating profit | 9,769 | 14,544 |
| Profit before tax | 9,123 | 13,640 |
| Income tax | 551 | 1,701 |
| Profit for the year | 14,854 | 11,939 |
| Profit attributable to shareholders | 14,850 | 11,941 |
| Filing | 20-F | 20-F |
USD million, from the 20-F on the SEC's EDGAR, linked in the last row, on the IFRS tags the company filed. A line the company does not file under the standard tag is left out rather than estimated.
USD per ordinary share, as filed.
Cash flow
| Year to | Dec 2023 | Dec 2024 |
|---|---|---|
| Cash from operations | 14,458 | 17,619 |
| Purchase of property, plant and equipment | 1,060 | 1,366 |
| Free cash flow | 13,398 | 16,253 |
| Dividends paid | 7,255 | 7,624 |
| Filing | 20-F | 20-F |
USD million. Free cash flow is cash from operations less the purchase of property, plant and equipment, arithmetic on the two filed lines.
Balance sheet at year end
| Year to | Dec 2023 | Dec 2024 |
|---|---|---|
| Total assets | 99,945 | 102,246 |
| Equity attributable to shareholders | 46,667 | 44,046 |
| Cash and cash equivalents | 13,393 | 11,459 |
| Borrowings, as filed | 20,627 | 24,722 |
| Lease liabilities | 1,828 | 1,803 |
| Inventories | 5,913 | 5,723 |
| Goodwill | 23,341 | 24,756 |
| Filing | 20-F | 20-F |
USD million, at each fiscal year end.
Ratios on the filed lines
Arithmetic on the filed lines of the same year.
Every annual report here
- Year to 31 December 2025
- Year to 31 December 2024, this page
- Year to 31 December 2023
- Year to 31 December 2022
- Year to 31 December 2021
- Year to 31 December 2020
- Year to 31 December 2019
- Year to 31 December 2018
- Year to 31 December 2017
- Year to 31 December 2016
Source
20-F for the year to 31 December 2024, filed 4 February 2026, accession 0001114448-26-000004: the filing on EDGAR. All of Novartis AG's filings: EDGAR company page. The figures are in US dollars as filed.
The same record on your computer
GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.